BioCentury | Dec 21, 2018
Clinical News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

...Tokyo:4507), Osaka, Japan Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Besremi ropeginterferon alfa-2b (AOP2014, P1101...
...Compound #), brentuximab vedotin (Generic), Adcetris (Other) biosimilar bevacizumab (PF-06439535) Ilaris, canakinumab (ACZ885) Mulpleta, lusutrombopag (S-888711) PEG-P-INF alfa-2b, Ropeginterferon alfa 2b (AOP2014, P1101) Rubraca...
BioCentury | Dec 14, 2018
Company News

CHMP backs Besremi for polycythemia vera, two Shionogi drugs

...Compound #), brentuximab vedotin (Generic), Adcetris (Other) biosimilar bevacizumab (PF-06439535) Ilaris, canakinumab (ACZ885) Mulpleta, lusutrombopag (S-888711) PEG-P-INF alfa-2b, Ropeginterferon alfa 2b (AOP2014, P1101) Rubraca...
BioCentury | Dec 30, 2016
Clinical News

Ropeginterferon alfa-2b: Final Ph III PROUD-PV data

...Vienna, Austria PharmaEssentia Corp. (TPEx:6446), Taipei, Taiwan Product: PEG-P-INF alfa-2b , Ropeginterferon alfa-2b ( AOP2014 , P1101...
...blood parameters, spleen size, disease-related symptoms and safety Status: Final Phase III data Milestone: NA Chris Lieu Ropeginterferon alfa 2b AOP...
BioCentury | Mar 16, 2015
Clinical News

PEG-P-INF alfa-2b: Completed Phase III enrollment

...Vienna, Austria PharmaEssentia Corp. (GreTai-E:6446), Taipei, Taiwan Product: PEG-P-INF alfa-2b , Ropeginterferon alfa 2b ( AOP2014 , P1101...
BioCentury | Dec 17, 2012
Clinical News

PEG-P-INF alfa-2b: Phase I/II data

...the Phase II portion of the open-label, Austrian Phase I/II PEGINVERA trial showed that subcutaneous AOP2014...
...including 5 complete response and 5 partial responses. Safety data from 41 patients showed that AOP2014...
...Pharmaceuticals AG , Vienna, Austria PharmaEssentia Corp. , Taipei, Taiwan Product: PEG-P-INF alfa-2b ( P1101 , AOP2014...
BioCentury | Dec 11, 2012
Clinical News

AOP Orphan reports Phase II polycythemia vera data

...patients in the Phase II portion of the Phase I/II PEGINVERA trial of its subcutaneous AOP2014...
...including five complete responses and five partial responses. Safety data from 41 patients showed that AOP2014...
...in Atlanta. Early next year, AOP plans to start the Phase III PROUD-PV trial of AOP2014...
BioCentury | Jun 23, 2008
Clinical News

Pharmaessentia preclinical data

...Four monkeys injected with P1101 peginterferon alfa-2b had detectable peginterferon levels after 2 weeks compared with...
...2 of 4 monkeys injected with marketed peginterferon. Pharmaessentia plans to submit an IND for P1101...
...treat HBV and HCV next quarter. Pharmaessentia Corp. , Taipei, Taiwan Product: Peginterferon alfa-2b ( P1101...
Items per page:
1 - 7 of 7